Emerging concepts in PD-1 checkpoint biology.

Emerging concepts in PD-1 checkpoint biology.
复制标题

PD-1检查点生物学中的新兴概念。

DOI:
10.1016/j.smim.2021.101480
复制
发表时间:
2021-03
影响因子:
7.8
通讯作者:
Freeman GJ
Freeman GJ
中科院分区:
医学2区
文献类型:
--
作者:
Pauken KE;Torchia JA;Chaudhri A;Sharpe AH;Freeman GJ

文献摘要

参考文献

被引文献

相似文献

PD - 1通路是免疫调节的基石。虽然PD - 1通路因其在慢性感染和癌症中导致T细胞耗竭的维持作用而受到相当多的关注,但PD - 1通路在调节T细胞耗竭之外的宿主免疫方面发挥着多种作用。在此,我们讨论PD - 1通路中新兴的概念,包括(1)PD - 1抑制剂对不同T细胞分化状态的影响,包括急性感染期间效应T细胞和记忆T细胞的发育,以及慢性感染和癌症期间的T细胞耗竭;(2)PD - 1在调节调节性T细胞(Treg)、自然杀伤细胞(NK细胞)和固有淋巴细胞(ILCs)中的作用;(3)PD - L1/B7 - 1和PD - L2/RGMb/轴突导向因子(neogenin)相互作用的功能。然后我们讨论新辅助PD - 1阻断在早期癌症治疗中的新兴应用,以及PD - 1阻断的时机如何改善临床结果。PD - 1及其相关配体的多种结合伙伴、受体和配体的广泛表达模式、PD - 1调节对细胞的不同影响(取决于位置和分化状态)以及PD - 1阻断的时机,都为PD - 1通路增加了额外的复杂性层次,并且是提高PD - 1通路疗法疗效和安全性的重要考虑因素。
The PD-1 pathway is a cornerstone in immune regulation. While the PD-1 pathway has received considerable attention for its role in contributing to the maintenance of T cell exhaustion in chronic infection and cancer, the PD-1 pathway plays diverse roles in regulating host immunity beyond T cell exhaustion. Here, we discuss emerging concepts in the PD-1 pathway, including (1) the impact of PD-1 inhibitors on diverse T cell differentiation states including effector and memory T cell development during acute infection, as well as T cell exhaustion during chronic infection and cancer (2) the role of PD-1 in regulating Treg cells, NK cells, and ILCs, and (3) the functions of PD-L1/B7-1 and PD-L2/RGMb/neogenin interactions. We then discuss the emerging use of neoadjuvant PD-1 blockade in the treatment of early-stage cancers and how the timing of PD-1 blockade may improve clinical outcomes. The diverse binding partners of PD-1 and its associated ligands, broad expression patterns of the receptors and ligands, differential impact of PD-1 modulation on cells depending on location and state of differentiation, and timing of PD-1 blockade add additional layers of complexity to the PD-1 pathway, and are important considerations for improving the efficacy and safety of PD-1 pathway therapeutics.
DOI: 10.1056/nejmra1911109
发表时间: 2020-09-17
期刊: The New England journal of medicine
影响因子: --
作者:
Bluestone JA;Anderson M
通讯作者: Anderson M
DOI: 10.4049/jimmunol.1003870
发表时间: 2011-06-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者:
Allie SR;Zhang W;Fuse S;Usherwood EJ
通讯作者: Usherwood EJ
DOI: 10.1084/jem.20180684
发表时间: 2018-10-01
期刊: The Journal of experimental medicine
影响因子: --
作者:
Brummelman J;Mazza EMC;Alvisi G;Colombo FS;Grilli A;Mikulak J;Mavilio D;Alloisio M;Ferrari F;Lopci E;Novellis P;Veronesi G;Lugli E
通讯作者: Lugli E
DOI: 10.1038/ni.3031
发表时间: 2014-12
期刊: Nature immunology
影响因子: 30.5
作者:
通讯作者: --
DOI: 10.1016/s1470-2045(18)30015-9
发表时间: 2018-02-01
期刊: LANCET ONCOLOGY
影响因子: 51.1
作者:
Amaria, Rodabe N.;Prieto, Peter A.;Wargo, Jennifer A.
通讯作者: Wargo, Jennifer A.